Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirikizumab - Eli Lilly and Company

Next Previous
Drug Profile

Mirikizumab - Eli Lilly and Company

Alternative Names: IL-23 antibody - Eli Lilly and Company; IL-23p19 antibody - Eli Lilly and Company; LY 3074828; Miri - Eli Lilly and Company; OMVOH; Omvoh

Latest Information Update: 30 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis; Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ulcerative colitis
  • Registered Crohn's disease
  • Discontinued Plaque psoriasis

Most Recent Events

  • 30 Apr 2025 Eli Lily and company plans a phase III trial for Crohn's disease and Obesity (Monotherapy or Combination therapy, Treatment experienced) in USA, Austria, Brazil, Belgium, Canada, Czech republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Romania, Slovakia, Spain, Turkey (IV) in June 2025 (NCT06937099) (EudraCT2024-520210-21-00)
  • 22 Apr 2025 Eli Lilly and Company plans the phase IIIb COMMIT-UC trial forUlcerative Colitis and Obesity (Treatment-experienced) (IV, SC), in June 2025 (NCT06937086)
  • 07 Feb 2025 Efficacy and adverse event data from the phase III VIVID-2 trial in Crohn's disease released by Eli Lilly and company

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top